AIM: To assess KIT and PDGFRA mutations frequencies in a Portuguese series of gastrointestinal stromal tumours (GISTs). METHODS: 78 GISTs were evaluated for CD117 expression and screened for mutations in KIT (exons 9, 11, 13, 14 and 17) and PDGFRA (exons 12, 14 and 18) genes. RESULTS: KIT activating mutations were identified in 44 (56%) of the 78 GISTs. Forty cases (91%) presented a mutation in KIT exon 11, and 4 (9%) in exon 9. One case showed a 4 bp deletion in intron 14. PDGFRA mutations were observed in 5 cases (6%): 2 (3%) in exon 12 and 3 (4%) in exon 18. Survival analysis was performed in 63 of the 78 GISTs. The presence of mutated KIT was significantly correlated with shorter survival of patients (p = 0.0460), and inversely associated with epithelioid histological type of GISTs (p = 0.0064). CONCLUSIONS: Overall, the incidence of both KIT and PDGFRA mutations in these Portuguese series was 63%, being in agreement with other studies, mainly of Iberian populations. The great majority of mutations were located in KIT exon 11, statistically associated with worse prognosis and indicative of favourable response to imatinib-based therapy in this Portuguese series of GISTs.
AIM: To assess KIT and PDGFRA mutations frequencies in a Portuguese series of gastrointestinal stromal tumours (GISTs). METHODS: 78 GISTs were evaluated for CD117 expression and screened for mutations in KIT (exons 9, 11, 13, 14 and 17) and PDGFRA (exons 12, 14 and 18) genes. RESULTS:KIT activating mutations were identified in 44 (56%) of the 78 GISTs. Forty cases (91%) presented a mutation in KIT exon 11, and 4 (9%) in exon 9. One case showed a 4 bp deletion in intron 14. PDGFRA mutations were observed in 5 cases (6%): 2 (3%) in exon 12 and 3 (4%) in exon 18. Survival analysis was performed in 63 of the 78 GISTs. The presence of mutated KIT was significantly correlated with shorter survival of patients (p = 0.0460), and inversely associated with epithelioid histological type of GISTs (p = 0.0064). CONCLUSIONS: Overall, the incidence of both KIT and PDGFRA mutations in these Portuguese series was 63%, being in agreement with other studies, mainly of Iberian populations. The great majority of mutations were located in KIT exon 11, statistically associated with worse prognosis and indicative of favourable response to imatinib-based therapy in this Portuguese series of GISTs.
Authors: António M Gouveia; Amadeu P Pimenta; Ana F Capelinha; Dionísio de la Cruz; Paula Silva; José M Lopes Journal: World J Surg Date: 2008-11 Impact factor: 3.352
Authors: Mara Silva; Isabel Veiga; Franclim R Ribeiro; Joana Vieira; Carla Pinto; Manuela Pinheiro; Bárbara Mesquita; Catarina Santos; Marta Soares; José Dinis; Lúcio Santos; Paula Lopes; Mariana Afonso; Carlos Lopes; Manuel R Teixeira Journal: BMC Med Date: 2010-05-14 Impact factor: 8.775
Authors: Adhemar Longatto-Filho; Céline Pinheiro; Olga Martinho; Marise A R Moreira; Luiz F J Ribeiro; Geraldo S Queiroz; Fernando C Schmitt; Fátima Baltazar; Rui M Reis Journal: BMC Cancer Date: 2009-06-29 Impact factor: 4.430
Authors: Olga Martinho; António Gouveia; Paula Silva; Amadeu Pimenta; Rui Manuel Reis; José Manuel Lopes Journal: Virchows Arch Date: 2009-08-25 Impact factor: 4.064
Authors: Nathália C Campanella; Ricardo Celestino; Ana Pestana; Cristovam Scapulatempo-Neto; Antonio Talvane de Oliveira; Maria José Brito; António Gouveia; José Manuel Lopes; Denise Peixoto Guimarães; Paula Soares; Rui M Reis Journal: Eur J Hum Genet Date: 2014-09-24 Impact factor: 4.246
Authors: Ricardo Celestino; Jorge Lima; Alexandra Faustino; João Vinagre; Valdemar Máximo; António Gouveia; Paula Soares; José Manuel Lopes Journal: Eur J Hum Genet Date: 2012-09-05 Impact factor: 4.246
Authors: O Martinho; A Longatto-Filho; M B K Lambros; A Martins; C Pinheiro; A Silva; F Pardal; J Amorim; A Mackay; F Milanezi; N Tamber; K Fenwick; A Ashworth; J S Reis-Filho; J M Lopes; R M Reis Journal: Br J Cancer Date: 2009-08-25 Impact factor: 7.640